景順:中國監管機構出台最新舉措 美國上市中概股風險稍為下降
中國證監會啟動《關於加強境內企業境外發行證券和上市相關保密和檔案管理工作的規定》的修訂工作。景順亞洲(日本除外)首席投資總監Mike Shiao認為,這是中國幫助解決美國上市ADR問題的重要一步,因為這已經持續了很長時間。修訂表明中國願意協助境外上市公司配合美國的審計要求,也表明中國當局正試圖在國家安全和全球金融市場的商業發展之間取得平衡。
他表示,在中國監管機構出台的最新舉措後,在美國上市的中國公司的風險稍為下降。在此發展之後,景順認為公司退市的可能性已經降低,有可能消除中國公司的重大風險,相信這種正面的發展可能觸發ADR股價的短期反彈。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.